Sun Pharma’s arm enters into settlement agreement with Actavis

06 Oct 2015 Evaluate

Sun Pharmaceutical Industries’ wholly-owned subsidiary - Ranbaxy Pharmaceuticals Inc. (Ranbaxy), along with its partners, Cipher Pharmaceuticals Inc. (Cipher) and Galephar Pharmaceutical Research, Inc. (Galephar) have entered into a settlement agreement with Actavis Group (Actavis) that dismisses the patent litigation suit relating to Actavis’ Abbreviated New Drug Application (ANDA) for a generic version of Absorica (isotretinoin capsules).

As part of the settlement agreement, Ranbaxy, Cipher, and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may begin selling its generic version of Absorica  in the US on December 27, 2020 (approximately nine months prior to the expiration of the patents in September 2021) or earlier under certain circumstances.

The settlement agreement is subject to review by the US Federal Trade Commission and the US Department of Justice.


 

Sun Pharma Inds. Share Price

1725.95 5.55 (0.32%)
02-Jan-2026 10:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1725.95
Dr. Reddys Lab 1245.00
Cipla 1507.95
Zydus Lifesciences 913.85
Lupin 2105.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×